Suppr超能文献

中药降低台湾非酒精性脂肪性肝病患者肝硬化发生率:一项倾向评分匹配队列研究。

Chinese Herbal Medicine Decreases Incidence of Cirrhosis in Patients with Non-Alcoholic Fatty Liver Disease in Taiwan: A Propensity Score-Matched Cohort Study.

机构信息

Department of Family Medicine, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.

School of Medicine, Tzu Chi University, Hualien, Taiwan.

出版信息

J Altern Complement Med. 2021 Jul;27(7):596-605. doi: 10.1089/acm.2020.0494. Epub 2021 Apr 27.

Abstract

Chinese herbal medicine (CHM) is quite popular in Asia. The purpose of this study is to investigate the benefits of decreasing the risk of cirrhosis in patients with non-alcoholic fatty liver disease (NAFLD) by using CHM. We performed a 1:3 propensity score-matched cohort study to analyze patients with NAFLD diagnosed between January 1, 1997 and December 31, 2011 through the Taiwanese National Health Insurance Research Database. Patients who received CHM therapy from the initial date of diagnosis of NAFLD to December 31, 2011 were included in the CHM group. Patients who were not treated with CHM during the same interval were categorized in the non-CHM group. Cox regression model was used to adjust for sex, age, comorbidities, and drug use. Hazard ratios were also compared between the two groups. A total of 13,072 patients were identified after 1:3 propensity score matching. The patients had similar basic characteristics. A lower cumulative incidence of cirrhosis was found in the CHM cohort (log-rank test,  < 0.0001). Finally, 176 patients in the CHM cohort (4.66 per 1000 person-years) and 582 patients in the non-CHM cohort (7.92 per 1000 person-years) developed cirrhosis (adjusted hazard ratios 0.63, 95% confidence interval 0.53-0.75). The effect of CHM to lower cirrhosis incidence was independent of sex, drug use, and comorbidities, including diabetes mellitus, hypertension, and cardiovascular diseases. Patients older than 40 years of age and without comorbidities such as chronic obstructive pulmonary disease, hyperlipidemia, alcoholism, tobacco use, or obesity also benefited from CHM. Our study is the first large-scale investigation in Taiwan that shows the association between patients with NAFLD and cirrhosis prevention after CHM intervention. The results may be useful for treatment and for decision making for patients and clinical doctors. Further restricted trials are needed to support our findings.

摘要

中草药(CHM)在亚洲非常受欢迎。本研究的目的是通过使用 CHM 来研究降低非酒精性脂肪性肝病(NAFLD)患者肝硬化风险的益处。我们进行了 1:3 的倾向评分匹配队列研究,通过台湾全民健康保险研究数据库分析了 1997 年 1 月 1 日至 2011 年 12 月 31 日期间诊断为 NAFLD 的患者。从 NAFLD 诊断的初始日期至 2011 年 12 月 31 日,接受 CHM 治疗的患者被纳入 CHM 组。在同一时间段内未接受 CHM 治疗的患者被归入非 CHM 组。Cox 回归模型用于调整性别、年龄、合并症和药物使用情况。还比较了两组之间的风险比。通过 1:3 的倾向评分匹配后,共确定了 13072 名患者。患者具有相似的基本特征。在 CHM 队列中发现肝硬化的累积发生率较低(对数秩检验,<0.0001)。最后,CHM 队列中有 176 名患者(每 1000 人年 4.66 例)和非 CHM 队列中有 582 名患者(每 1000 人年 7.92 例)发展为肝硬化(调整后的风险比 0.63,95%置信区间 0.53-0.75)。CHM 降低肝硬化发生率的效果独立于性别、药物使用和合并症,包括糖尿病、高血压和心血管疾病。年龄大于 40 岁且无慢性阻塞性肺疾病、高脂血症、酒精中毒、吸烟或肥胖等合并症的患者也从 CHM 中受益。我们的研究是台湾首次大规模调查,表明 CHM 干预后 NAFLD 患者与肝硬化预防之间存在关联。结果可能对治疗和患者及临床医生的决策有用。需要进一步的限制试验来支持我们的发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验